Russell Investments Group Ltd. Has $25.23 Million Holdings in Genmab A/S Sponsored ADR $GMAB

Russell Investments Group Ltd. cut its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 11.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 822,739 shares of the company’s stock after selling 111,328 shares during the period. Russell Investments Group Ltd. owned 0.13% of Genmab A/S worth $25,233,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Federated Hermes Inc. bought a new position in Genmab A/S in the 3rd quarter worth approximately $12,972,000. Oppenheimer Asset Management Inc. boosted its position in Genmab A/S by 24.1% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 315,862 shares of the company’s stock valued at $9,687,000 after buying an additional 61,311 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Genmab A/S by 17.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after buying an additional 135,814 shares during the last quarter. Eagle Global Advisors LLC increased its stake in shares of Genmab A/S by 16.3% in the 3rd quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock valued at $7,498,000 after buying an additional 34,175 shares during the period. Finally, Squarepoint Ops LLC increased its stake in shares of Genmab A/S by 636.3% in the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after buying an additional 81,434 shares during the period. 7.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GMAB. Jefferies Financial Group began coverage on Genmab A/S in a research note on Tuesday, February 17th. They set a “buy” rating and a $41.50 price target on the stock. Wells Fargo & Company initiated coverage on Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective for the company. Morgan Stanley began coverage on shares of Genmab A/S in a research report on Monday, February 16th. They set an “equal weight” rating and a $34.00 target price on the stock. HC Wainwright raised their target price on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Guggenheim lowered their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.58.

Genmab A/S Trading Down 3.0%

GMAB opened at $26.57 on Friday. The firm’s fifty day moving average is $31.05 and its two-hundred day moving average is $30.44. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The firm has a market cap of $17.07 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 1.12 and a beta of 0.94. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $35.43.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.